DCSIMG

Losses narrow at ReNeuron

  • by GARETH MACKIE
 

ReNeuron Group, the life sciences company conducting stem cell trials at Glasgow’s Southern General Hospital, has narrowed its first-half losses.

The Surrey-based firm, which is testing the effects of stem cells on stroke patients, posted a pre-tax loss of £3.3 million for the six months to 30 September, down from £3.4m a year earlier, thanks to lower research and development spending as it completed pre-clinical work on a treatment aimed at diabetics.

Lower spending helped the group’s cash position improve to £6.7m, up from £6.5m a year ago, and it said its current financial resources are expected to last into the fourth quarter of 2013.

ReNeuron said it was pursuing a range of funding options, including the use grants, to reduce its reliance on equity-based funding for its core therapeutic programmes.

Chairman Bryan Morton said: “We believe that our stem cell product candidates embody characteristics that are critical for the development of scalable and affordable off-the-shelf cell-based therapies that can address large un-met medical and patient needs.

“We therefore strongly believe in the commercial potential of these therapeutic candidates and we look forward to reporting future progress towards realising that potential.”

 

Comments

 
 

Back to the top of the page